Vicodene Studies
Click on a product to view scientific studies.
Vicodene Maintains Healthy Brain Function
NSAIDs, thiazolidinediones, and PGJ2, all of which are PPARg agonists, were shown to inhibit the b-amyloid-stimulated expression of the genes for IL-6 and TNF-a. Patients with early stage of Alzheimer's disease (AD) were given either 250mg of Vicodene or placebo and undergone various Neuropsychological tests. Placebo group show a significant cognitive deterioration, which is the normal course of AD, while the Vicodene group is showing no change or improvement test scores suggesting that Vicodene may have application for maintaining healthy brain function by stimulates the PPAR-g receptor.
Vicodene Maintain Healthy Inflammatory Response
In vitro, Vicodene is shown to inhibit T cell proliferation, Interferon gamma, and Interleukin 2 (IL-2). Vicodene significantly delayed the onset and reduced the severity of Experimental Autoimmune Encephalomyelitis (EAE) by impairing T cell activation as well as antibody production against myelin antigens. After 3 weeks the Interferon gamma, Interleukin 2, and T Cells all return to normal.
Vicodene interferes with DNA binding of NF-kB
Nuclear factor kappa B (NF- kB) regulates our inflammatory and immune response. Vicodenecan be useful in maintaining healthy inflammatory response by inhibiting the NF-kB binding with DNA, and thus reducing the pro-inflammatory protein expression, such as COX-2.
Vicodene reduces pro-inflammatory cytokines and protects against cell death
Vicodene reduces Pro-inflammatory cytokines Interferon gamma and Interleukin 2 production in murine T-cells and protects against cell apoptosis. The expression ICAM-1, iNOS, COX-2 and proinflammatory cytokine are controlled by mitogen-activated proteinkinase (MAPK) such as ERK1/2. Vicodene reduced ERK1/2 and could be useful in inhibiting ICAM-1, iNOS, COX-2, and other cytokines that are controlled by MARK.
Vicodene increase cellular immune response
The immunostimulatory effect of Vicodene at low doses has shown an increase of antigen specific and nonspecific immune response in mice. Vicodene can also be used for the prevention of common colds (a minimum of 15-25 mg of Vicodene corresponding to a dose of 0.3mg/Kg/day of Vicodene in healthy individuals. The increase in the cellular proliferation, IFN-g and IL-2 production in T-cells cultured with Vicodene indicate that Vicodene could be a stimulant of immune system, specifically through of Th1 response.
Vicodene as prevention of common cold
After 3 month treatment, volunteers receiving 15mg of Vicodene daily showed a significant lower incidence of common cold as compared to the placebo group indicating possible immunostimulating effect (29.63% vs. 63.3%). At low dosage, Vicodene were able to significantly increase the production of IFN gamma and IL-2 without modifying Th2 antibody (IL-2, IL-10 cytokines) production. In addition, RNA messenger for Interferon gamma was also increased. Interferon gamma is the first line of defense against viral infection such as Influenza, and is activated by T cell. In this study we have also found that at low dosage, Vicodene activates T cell, and increase Interleukin 2 (IL-2) cytokines. IL-2 assists T-cells to kill viral invaders and makes infection-fighting cells multiply and mature.